Plain Language Summaries
@PlainLangSumm
Updates about the #OpenAccess #PlainLanguageSummaries initiative at Taylor and Francis.
Interesting review looking at how palbociclib works for older breast cancer patients with HR+/HER2- disease. hubs.ly/Q03T2K050 #PlainLanguageSummary #BreastCancer
Researchers evaluated an innovative cancer treatment for urothelial cancer patients who had limited options, it looked at effectiveness when standard treatments like cisplatin and immunotherapy weren't suitable hubs.ly/Q03Sqy5j0 #PLSP #BladdercCancer
New plain language summary explores innovative approach to treating severe atopic dermatitis. Unlike existing therapies, this treatment targets the OX40 ligand immune pathway for patients needing alternatives to topical medications. hubs.ly/Q03T27Sj0 #PLSP #Eczema
New treatment option for myelodysplastic syndrome, Imetelstat showed promise in Phase 3 trials for transfusion-dependent patients. Learn more on the research here >>> hubs.ly/Q03TyPZV0 #PlainLanguageSummary #Hematology #RareBloodCancer
How does vagus nerve stimulation actually work for epilepsy? New research dives into the mechanisms behind this 30-year-old treatment. Read here 👇 hubs.ly/Q03Tyy8T0 #PlainLanguageSummary #Epilepsy #Neurotherapeutics
LOCK IT-100 study tested whether taurolidine/heparin solution prevents serious bloodstream infections in dialysis patients. Read the full research here >>> hubs.ly/Q03TxYxQ0 #PlainLanguageSummary #KidneyDisease #Nephrology
New LUMINA-1 study tested garetosmab for fibrodysplasia ossificans progressiva (FOP), a rare condition where muscles turn to bone, plus evaluated bone imaging methods hubs.ly/Q03T2S-g0 #PLSP #RareDiseases
New insights on managing talquetamab-related effects in multiple myeloma patients from MonumenTAL-1 trial. Learn more👇 hubs.ly/Q03T2Lvb0 #PlainLanguageSummary #MultipleMyeloma
New analysis of palbociclib data for aging breast cancer patients with hormone receptor-positive disease. hubs.ly/Q03T2J450 #PlainLanguageSummary #BreastCancer
Real-world evidence from Global aHUS Registry shows safe transition between two complement inhibitors for rare kidney disease. 60 patients switched treatments with stable disease markers and no need for dialysis or transplant, learn more👇 hubs.ly/Q03T2dPF0 #PLSP
Addressing unmet needs in eczema care, this clinical study evaluated a targeted antibody treatment for moderate-to-severe cases. Research focused on efficacy, safety, and duration of symptom control hubs.ly/Q03T26LM0 #PlainLanguageSummary #EczemaResearch
This PLSP highlights targeted therapy research for locally advanced/metastatic bladder cancer. The study focused on Cohort 2 patients needing alternatives after immunotherapy progression and cisplatin intolerance hubs.ly/Q03SqxRx0 #PLSP #BladdercCancer
New meta-analysis examines safety data from over 20K participants across 4 clinical trials. Study evaluated adverse events in patients with type 2 diabetes, heart failure, and chronic kidney disease.. Read here >> hubs.ly/Q03NqBdW0 #PLSP #DiabetesResearch
What happens when immunotherapy stops working? Research examines alternative treatment for metastatic urothelial cancer patients with FGFR2/3 mutations. Read the full summary here👇 hubs.ly/Q03Nqlkt0 #PlainLanguageSummary #BladderCancer
This summary reveals findings from major safety analysis involving over 20K participants. It provides valuable data on medication tolerability across three key patient populations with chronic conditions. Read here >> hubs.ly/Q03NqrWM0 #PLSP #DiabetesResearch
🧬 New research explores targeted therapy vs chemotherapy for advanced bladder cancer patients with FGFR2/3 alterations who've progressed after immunotherapy. Read the full details here👇 hubs.ly/Q03Nqhbg0 #PlainLanguageSummary #BladderCancer
American Academy of Sleep Medicine revises restless legs syndrome guidelines after a decade of evidence shows dopamine agonists may provide short-term relief but worsen symptoms over time. Full details in new research hubs.ly/Q03Hk27g0 #PLSP #SleepDisorders
In the DISCOVERY study, patients with C3G received pegcetacoplan for 48 weeks. Pegcetacoplan blocked the complement cascade, improved proteinuria, and stabilized kidney function. hubs.ly/Q03GWqlG0 #PlainLanguageSummary
Research details pivotal clinical evidence supporting new treatment option for Friedreich ataxia. It shows the therapy effectively slows progression of this inherited movement disorder, with manageable side effects allowing continued treatment. hubs.ly/Q03Kwfsd0 #PLSP
Study investigates clinical consequences of switching between apixaban and rivaroxaban in non-valvular atrial fibrillation. Research provides much-needed evidence on outcomes of anticoagulant transitions often necessitated by medical or practical factors. hubs.ly/Q03GWmnV0
United States الاتجاهات
- 1. Thanksgiving 2.17M posts
- 2. Dan Campbell 4,552 posts
- 3. Lions 87.6K posts
- 4. Jack White 7,472 posts
- 5. Goff 9,074 posts
- 6. Jordan Love 9,464 posts
- 7. #GoPackGo 7,406 posts
- 8. Jamo 4,555 posts
- 9. Wicks 5,901 posts
- 10. #GBvsDET 4,132 posts
- 11. Jameson Williams 2,394 posts
- 12. Watson 13.9K posts
- 13. Gibbs 8,398 posts
- 14. #OnePride 6,628 posts
- 15. Thankful 442K posts
- 16. Green Bay 7,047 posts
- 17. Turkey 282K posts
- 18. Nixon 5,396 posts
- 19. Parsons 4,449 posts
- 20. Amon Ra 3,106 posts
Something went wrong.
Something went wrong.